| Overview |
| bs-0279R-Cy7 |
| VEGF Polyclonal Antibody, Cy7 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F) |
| Human, Mouse, Rat, Pig, Goat, Others |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human VEGF |
| 27-120/232 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7422 |
| P15692 |
| Secreted |
| VPF; VEGF; MVCD1; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VEGFA |
| Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
Powered by Bioz